Raymond James上调艾伯维目标价至250美元

Core Viewpoint - Raymond James has raised AbbVie's target price from $236 to $250, reaffirming an "Outperform" rating [1] Group 1 - The target price adjustment reflects a positive outlook on AbbVie's performance in the market [1] - The reaffirmation of the "Outperform" rating indicates confidence in AbbVie's growth potential [1]